Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
39.97%
0%
39.97%
6 Months
4.7%
0%
4.7%
1 Year
5.06%
0%
5.06%
2 Years
-3.83%
0%
-3.83%
3 Years
-52.04%
0%
-52.04%
4 Years
-77.15%
0%
-77.15%
5 Years
-83.62%
0%
-83.62%
Advicenne SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.99%
EBIT Growth (5y)
6.45%
EBIT to Interest (avg)
-9.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
-0.10
Tax Ratio
7.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
NA
EV to EBIT
-3.09
EV to EBITDA
-3.56
EV to Capital Employed
NA
EV to Sales
3.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
NA
ROE (Latest)
NA
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
4.50
2.30
95.65%
Operating Profit (PBDIT) excl Other Income
-5.50
-10.30
46.60%
Interest
1.30
0.80
62.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.00
-11.50
39.13%
Operating Profit Margin (Excl OI)
-1,229.70%
-4,581.80%
335.21%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 95.65% vs -14.81% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 39.13% vs 7.26% in Dec 2022
About Advicenne SA 
Advicenne SA
Pharmaceuticals & Biotechnology
ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Company Coordinates 
Company Details
2 Rue Briconnet , NIMES None : 30000
Registrar Details






